BCH timeline
Every BCH batch the index holds, newest manufacture date first, with the supplier's declared purity beside the median of the index's independent observations of the same lot.
| Lot | Compound | Manufactured | Quarter | Tests | Independent median | Spread (pp) | COA purity | Divergence (pp) | |
|---|---|---|---|---|---|---|---|---|---|
| BCH-2607-H5235 | CJC-1295 with DAC | 07 Jul 2026 | 2026-Q3 | 9 | 97.63 | 0.45 | 98.00 | +0.37 | |
| BCH-2603-Y4946 | GHRP-6 | 28 Mar 2026 | 2026-Q2 | 4 | 98.76 | 0.47 | 98.50 | -0.26 | |
| BCH-2603-G4350 | BPC-157 | 10 Mar 2026 | 2026-Q3 | 12 | 98.59 | 1.67 | 98.50 | -0.09 | |
| BCH-2603-L5474 | BPC-157 | 03 Mar 2026 | 2026-Q3 | 3 | 98.04 | 0.81 | 98.19 | +0.15 | |
| BCH-2601-U5146 | MOTS-c | 26 Jan 2026 | 2026-Q1 | 6 | 98.16 | 0.99 | 98.03 | -0.13 | |
| BCH-2601-G4997 | MK-677 (Ibutamoren mesylate) | 07 Jan 2026 | 2026-Q1 | 1 | 97.90 | n<2 | 98.38 | +0.48 | |
| BCH-2511-L3743 | MOTS-c | 28 Nov 2025 | 2026-Q2 | 3 | 97.34 | 0.30 | 97.00 | -0.34 | |
| BCH-2511-G5204 | MK-677 (Ibutamoren mesylate) | 13 Nov 2025 | 2026-Q2 | 2 | 98.68 | 0.34 | 98.76 | +0.08 | SHARED BULK |
| BCH-2511-D5168 | MGF | 03 Nov 2025 | 2026-Q2 | 4 | 99.22 | 0.87 | 99.71 | +0.49 | |
| BCH-2510-P5124 | MK-677 (Ibutamoren mesylate) | 20 Oct 2025 | 2025-Q4 | 1 | 97.95 | n<2 | 97.94 | -0.01 | |
| BCH-2510-P4971 | Ipamorelin | 10 Oct 2025 | 2026-Q1 | 2 | 99.12 | 0.39 | 98.54 | -0.58 | |
| BCH-2510-F4167 | Gonadorelin | 08 Oct 2025 | 2025-Q4 | 14 | 98.89 | 1.06 | 99.16 | +0.27 | |
| BCH-2509-A4594 | Cagrilintide | 29 Sep 2025 | 2025-Q4 | 11 | 99.12 | 1.03 | 98.88 | -0.24 | |
| BCH-2509-K4227 | AOD-9604 | 28 Sep 2025 | 2025-Q4 | 3 | 98.27 | 0.40 | 98.15 | -0.12 | |
| BCH-2509-E4364 | TB-500 | 02 Sep 2025 | 2026-Q1 | 1 | 99.79 | n<2 | 99.90 | +0.11 | |
| BCH-2508-H4066 | BPC-157 | 23 Aug 2025 | 2025-Q4 | 3 | 98.58 | 0.26 | 98.92 | +0.34 | |
| BCH-2508-M4472 | GHRP-2 | 07 Aug 2025 | 2026-Q1 | 9 | 98.77 | 0.95 | 99.09 | +0.32 | |
| BCH-2508-A5665 | Tirzepatide | 04 Aug 2025 | 2025-Q3 | 3 | 99.03 | 0.20 | 99.12 | +0.09 | |
| BCH-2508-X4357 | L-Glutathione (reduced) | 01 Aug 2025 | 2025-Q3 | 1 | 97.44 | n<2 | 97.84 | +0.40 | |
| BCH-2506-G4536 | Pemvidutide | 16 Jun 2025 | 2025-Q3 | 1 | 97.97 | n<2 | 98.28 | +0.31 | |
| BCH-2506-D4413 | BPC-157 | 10 Jun 2025 | 2025-Q4 | 10 | 99.12 | 0.78 | 99.34 | +0.22 | |
| BCH-2505-Y5388 | Semaglutide | 25 May 2025 | 2025-Q4 | 11 | 98.03 | 1.75 | 98.50 | +0.47 | |
| BCH-2505-J4599 | MOTS-c | 13 May 2025 | 2025-Q2 | 5 | 98.58 | 1.06 | 98.48 | -0.10 | |
| BCH-2502-A4465 | CJC-1295 (no DAC) | 10 Feb 2025 | 2025-Q1 | 5 | 98.02 | 0.82 | 98.88 | +0.86 | SHARED BULK |
| BCH-2502-Y5639 | L-Glutathione (reduced) | 05 Feb 2025 | 2025-Q2 | 1 | 97.88 | n<2 | 97.84 | -0.04 | |
| BCH-2502-H4585 | PT-141 (Bremelanotide) | 01 Feb 2025 | 2025-Q2 | 1 | 99.93 | n<2 | 99.32 | -0.61 | |
| BCH-2501-B4807 | Hexarelin | 24 Jan 2025 | 2025-Q2 | 3 | 97.97 | 0.78 | 98.31 | +0.34 | |
| BCH-2501-D4197 | Tirzepatide | 20 Jan 2025 | 2025-Q2 | 11 | 97.25 | 1.33 | 97.32 | +0.07 | |
| BCH-2412-Y5177 | Retatrutide | 10 Dec 2024 | 2025-Q2 | 3 | 97.02 | 1.53 | 97.16 | +0.14 | |
| BCH-2407-M4711 | Selank | 17 Jul 2024 | 2024-Q3 | 1 | 98.86 | n<2 | 99.30 | +0.44 | |
| BCH-2407-F4650 | Tirzepatide | 14 Jul 2024 | 2024-Q4 | 9 | 97.33 | 1.41 | 97.42 | +0.09 | |
| BCH-2406-Y4179 | BPC-157 | 16 Jun 2024 | 2024-Q3 | 4 | 98.61 | 1.24 | 98.52 | -0.09 | |
| BCH-2406-E5279 | CJC-1295 with DAC | 07 Jun 2024 | 2024-Q4 | 7 | 98.52 | 0.64 | 98.27 | -0.25 | |
| BCH-2405-R4888 | VIP | 18 May 2024 | 2024-Q3 | 9 | 97.43 | 1.33 | 97.26 | -0.17 | |
| BCH-2405-U4366 | Semaglutide | 02 May 2024 | 2024-Q2 | 8 | 97.93 | 1.15 | 97.80 | -0.13 | |
| BCH-2404-N5218 | Tirzepatide | 30 Apr 2024 | 2024-Q3 | 11 | 97.63 | 1.28 | 97.97 | +0.34 | |
| BCH-2402-K5559 | Semaglutide | 17 Feb 2024 | 2024-Q3 | 2 | 98.69 | 0.50 | 98.21 | -0.48 | |
| BCH-2402-C5045 | Cagrilintide | 01 Feb 2024 | 2024-Q2 | 8 | 98.02 | 1.01 | 97.72 | -0.30 | |
| BCH-2310-K5538 | Afamelanotide | 17 Oct 2023 | 2024-Q1 | 7 | 97.86 | 1.30 | 97.74 | -0.12 |